Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-30

I'm not sure how much in total, but last quarterly stated $300k revenue from NanaBis and NanoCBD through the SAS scheme.

My understanding is that SAS is specifically designed for compassionate access to unregistered drugs, and prohibits any form of marketing or promotion for commercial purposes, so sales revenue through this system will probably never be massive.

The big upside is Medlab gets real world observational data from over 1200 patients using NanaBis which supports their new drug application, and if NanaBis is approved by the TGA, any competing products that aren't approved can no longer be sold under the SAS for that medical purpose. Regulatory approval is very slow and expensive, but it's ultimately worth it.